Evidence map›Paper›PMID 35677426›Full record

ReviewFrontiers in pharmacology2022

Anti-Inflammatory Activities of Betulinic Acid: A Review.

José Fernando Oliveira-Costa, Cássio Santana Meira, Maria Vitória Gomes das Neves, Bruna Padilha Zurita Claro Dos Reis, Milena Botelho Pereira Soares

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Comparative Metabolite Profiling ofMolecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Chaga Mushroom (Journal of microbiology and biotechnology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Isolation, purification and characterization of betulinic acid derivative from the root bark ofInternational journal of biochemistry and molecular biology · 2026
    Article
  10. Betulinic Acid-EnrichedAntioxidants (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

José Fernando Oliveira-CostaCenter for Infusions and Specialized Medicines of Bahia, Bahia State Health Department, Salvador, Brazil.
Cássio Santana MeiraSENAI Institute of Innovation in Health Advanced Systems (ISI SAS), University Center SENAI/CIMATEC, Salvador, Brazil.
Maria Vitória Gomes das NevesGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Bruna Padilha Zurita Claro Dos ReisGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Milena Botelho Pereira SoaresSENAI Institute of Innovation in Health Advanced Systems (ISI SAS), University Center SENAI/CIMATEC, Salvador, Brazil.
Fundação Oswaldo Cruz · BRServiço Nacional de Aprendizagem Industrial · BRUniversidade do Estado da Bahia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory diseases have a high prevalence and has become of great interest due to the increase in life expectancy and the costs to the health care system worldwide. Chronic diseases require long-term treatment frequently using corticosteroids and non-steroidal anti-inflammatory drugs, which are associated with diverse side effects and risk of toxicity. Betulinic acid, a lupane-type pentacyclic triterpene, is a potential lead compound for the development of new anti-inflammatory treatments, and a large number of derivatives have been produced and tested. The potential of betulinic acid and its derivatives has been shown in a number of pre-clinical studies using different experimental models. Moreover, several molecular mechanisms of action have also been described. Here we reviewed the potential use of betulinic acid as a promissory lead compound with anti-inflammatory activity and the perspectives for its use in the treatment of inflammatory conditions.

Indexed as

anti-inflammatory activitybetulinic acidimmunomodulationinflammationterpenoids

Identifiers

PMID35677426
PMCPMC9168372
OpenAlexW4281298759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.